Benitec Biopharma (BNTC) announced that it has commenced an underwritten public offering of its common stock and intends to conduct a concurrent registered direct offering of its common stock with long-term investor Suvretta Capital. The offerings are expected to close on November 7, subject to customary closing conditions. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Leerink Partners, TD Cowen and Evercore ISI are acting as bookrunning managers for the proposed offering.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Positive Buy Rating for BB-301 Driven by Promising Trial Results and Potential Market Acceleration
- Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright
- Benitec Biopharma price target raised to $22 from $20 at Citizens JMP
- Benitec Biopharma’s BB-301 Receives FDA Fast Track
- Benitec provide interim clinical results for BB-301 Phase 1b/2a trial of BB-301